Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Rybak

Showing results (191-200 of 2,583) with videos related to

Pageof 259
Sort By:
Hearing Research|January 1, 1987
Some organic acids attenuate the effects of furosemide on the endocochlear potentialL P Rybak, C Whitworth
Polski Tygodnik Lekarski (Warsaw, Poland : 1960)|January 3, 1983
[Accidental hypothermia]W Lubczyńska-Kowalska, M Rybak
American Journal of Otolaryngology|September 1, 1988
Quinine reduces noxious cochlear effects of furosemide and ethacrynic acidL P Rybak, C Whitworth
Postepy Higieny I Medycyny Doswiadczalnej (Online)|March 12, 2005
[Mechanisms of immunosuppression in leukemia]Włodzimierz Luczyński, Maryna Krawczuk-Rybak
Plants (Basel, Switzerland)|January 21, 2023
Nanopriming of Barley Seeds-A Shotgun Approach to Improve Germination under Salt Stress Conditions by Regulating of Reactive Oxygen SpeciesDanuta Cembrowska-Lech, Kinga Rybak
Antimicrobial Agents and Chemotherapy|May 23, 2003
Linezolid and vancomycin, alone and in combination with rifampin, compared with moxifloxacin against a multidrug-resistant and a vancomycin-tolerant Streptococcus pneumoniae strain in an in vitro pharmacodynamic modelRaymond Cha, Michael J Rybak
Current Opinion in Otolaryngology & Head and Neck Surgery|September 23, 2003
Ototoxicity: bioprotective mechanismsLeonard P Rybak, Thomas Kelly
Annals of the New York Academy of Sciences|June 8, 2000
Ototoxicity. Amelioration by protective agentsL P Rybak, S Somani
Advances in Medical Sciences|January 26, 2008
Are elevated serum levels of IGFBP-2 after intensive chemotherapy of childhood acute lymphoblastic leukemia a risk factor of relapse?A Kitszel, M Krawczuk-Rybak
Antimicrobial Agents and Chemotherapy|March 21, 2018
β-Lactam Combinations with Vancomycin Show Synergistic Activity against Vancomycin-Susceptible Staphylococcus aureus, Vancomycin-Intermediate S. aureus (VISA), and Heterogeneous VISANikki Tran, Michael J Rybak
Pageof 259

Showing results (191-200 of 2,583) with videos related to

Sort By:
Pageof 259
Hearing Research|January 1, 1987
Some organic acids attenuate the effects of furosemide on the endocochlear potentialL P Rybak, C Whitworth
Polski Tygodnik Lekarski (Warsaw, Poland : 1960)|January 3, 1983
[Accidental hypothermia]W Lubczyńska-Kowalska, M Rybak
American Journal of Otolaryngology|September 1, 1988
Quinine reduces noxious cochlear effects of furosemide and ethacrynic acidL P Rybak, C Whitworth
Postepy Higieny I Medycyny Doswiadczalnej (Online)|March 12, 2005
[Mechanisms of immunosuppression in leukemia]Włodzimierz Luczyński, Maryna Krawczuk-Rybak
Plants (Basel, Switzerland)|January 21, 2023
Nanopriming of Barley Seeds-A Shotgun Approach to Improve Germination under Salt Stress Conditions by Regulating of Reactive Oxygen SpeciesDanuta Cembrowska-Lech, Kinga Rybak
Antimicrobial Agents and Chemotherapy|May 23, 2003
Linezolid and vancomycin, alone and in combination with rifampin, compared with moxifloxacin against a multidrug-resistant and a vancomycin-tolerant Streptococcus pneumoniae strain in an in vitro pharmacodynamic modelRaymond Cha, Michael J Rybak
Current Opinion in Otolaryngology & Head and Neck Surgery|September 23, 2003
Ototoxicity: bioprotective mechanismsLeonard P Rybak, Thomas Kelly
Annals of the New York Academy of Sciences|June 8, 2000
Ototoxicity. Amelioration by protective agentsL P Rybak, S Somani
Advances in Medical Sciences|January 26, 2008
Are elevated serum levels of IGFBP-2 after intensive chemotherapy of childhood acute lymphoblastic leukemia a risk factor of relapse?A Kitszel, M Krawczuk-Rybak
Antimicrobial Agents and Chemotherapy|March 21, 2018
β-Lactam Combinations with Vancomycin Show Synergistic Activity against Vancomycin-Susceptible Staphylococcus aureus, Vancomycin-Intermediate S. aureus (VISA), and Heterogeneous VISANikki Tran, Michael J Rybak
Pageof 259